Rituxan

June 8, 2018

Imbruvica-Rituxan Combo Significantly Delays Progression of Rare Type of Lymphoma in Phase 3 Trial

News

A combination of Imbruvica (ibrutinib) and Rituxan (rituximab) significantly extends the time to disease worsening or death in patients with a rare type of lymphoma called Waldenström’s macroglobulinemia, a Phase 3 trial ... Read more

June 4, 2018

Alexo Begins Testing ALX148 Combinations in Phase 1 Trial of NHL, Solid Tumors

News

Alexo Therapeutics has started treating patients in the combination part of its Phase 1 trial, which will test multiple combinations of ALX148 with targeted antibody therapies — including Keytruda (pembrolizumab), Herceptin ... Read more

May 29, 2018

Arzerra-Bendamustine Combo Fails to Delay Disease Worsening in Indolent Non-Hodgkin’s Lymphoma Patients in Phase 3 Trial

News

Adding Arzerra (ofatumumab) to the chemotherapy agent bendamustine did not delay disease progression or death in indolent non-Hodgkin’s lymphoma patients whose disease failed to respond to Rituxan (rituximab) treatment, according to a ... Read more

May 25, 2018

Revlimid-Rituxan Combo Could Replace Chemo as Follicular Lymphoma Therapy, Phase 3 Trial Suggests

News

A combination of Rituxan (rituximab) and Revlimid (lenalidomide) is similarly effective and has a better safety profile than the standard first-line regimen — chemotherapy and Rituxan — for follicular lymphoma patients, a Phase 3 ... Read more

April 26, 2018April 26, 2018

Nearly Half of NHL Patients in Phase 1 Trial Respond to ALT-803, Rituxan Combo, Results Show

News

A combination of Rituxan (rituximab) and the experimental agent ALT-803 leads to a response rate of 48% in patients with relapsed or refractory indolent non-Hodgkin’s lymphoma, according to preliminary data from a Phase ... Read more

April 10, 2018April 10, 2018

Phase 2b Trial of Betalutin in Relapsed Follicular Lymphoma Patients on Track, Nordic Says

News

A Phase 2b trial evaluating Betalutin — a tumor-targeting antibody labeled with a type of radiation — as a third-line therapy for follicular lymphoma patients will conclude a little later than ... Read more

February 23, 2018February 23, 2018

Imbruvica Only Moderately Effective in Relapsed Follicular Lymphoma Patients, Phase 2 Trial Shows

News

Imbruvica (ibrutinib) is only moderately effective against tumors in patients with relapsed follicular lymphoma, and certain clinical and genetic factors may have an impact on patient response, according to results ... Read more

February 9, 2018February 9, 2018

Triple Combo Therapy Improves Outcomes for Certain Mantle Cell Lymphoma Patients

News

Combining Imbruvica (ibrutinib) with Revlimid (lenalidomide) and Rituxan (rituximab) may improve the poor outcomes of relapsed mantle cell lymphoma patients with certain genetic alterations, a Phase 2 trial suggests. But ... Read more

January 29, 2018January 29, 2018

Pfizer’s Rituxan Biosimilar Equally Effective at Treating Follicular Lymphoma, Trial Shows

News

Pfizer‘s biosimilar therapy candidate PF-05280586 has shown equal effectiveness as Rituxan (rituximab) at treating indolent follicular lymphoma in a Phase 3 trial, the company announced. Indolent, or slow-growing, follicular lymphoma is ... Read more

December 7, 2017

Polatuzumab Vedotin Addition Makes Stark Difference for DLBCL Patients, Studies Show

News

Adding the investigational treatment polatuzumab vedotin to a therapy of Bendeka (bendamustine) and Rituxan (rituximab) made patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) respond better to the ... Read more